 |
|
Vaccine Aimed at African HIV to Begin Trials
Joan Stephenson, PhD
JAMA. 2000;284:683.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Durban, South Africa—A new HIV/AIDS experimental vaccine—the first designed to specifically target the major HIV subtype sweeping through Africa—has been given the green light by British authorities to undergo human safety trials this month.
The trials, announced here at the XIII International AIDS Conference, will involve a DNA vaccine candidate with a mechanism that researchers hope will mimic the natural immune response of a small group of sex workers in Nairobi—women who were found, despite frequent exposure to HIV over many years, to be resistant to infection. The effort is the result of a partnership between research teams at the University of Oxford, led by Andrew McMichael, MD, PhD, and at the University of Nairobi in Kenya, led by J. J. Bwayo, MD.
Although more than two dozen vaccine candidates have undergone testing in humans, the new experimental vaccine is the first one based on HIV . . . [Full Text of this Article]
|
